

WORLDWIDE APPROVAL

TRIUMEQ Tablets

Algeria	Guyana	Saudi Arabia
Argentina	Hong Kong	Serbia
Armenia	Israel	Singapore
Aruba	Jamaica	South Africa
Australia	Japan	Switzerland
Bahrain	Kazakhstan	Taiwan
Botswana	Kenya	Thailand
Brazil	Lebanon	Trinidad and Tobago
Canada	Macau	Turkey
Chile	Macedonia	Uganda
China	Namibia	Ukraine
Colombia	New Zealand	United Arab Emirates
Costa Rica	Nigeria	United Kingdom
Curacao	Oman	United States of America
Dominican Republic	Pakistan	Uruguay
Ecuador	Panama	Uzbekistan
European Union	Peru	
Georgia	Qatar	
Ghana	Republic of Korea	

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 24 November 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.